Business
Cerus Corporation Announces New Manufacturing and Supply Agreement With Fresenius Kabi For INTERCEPT Blood System Sets
10-Year Collaboration Will Support Growing Global Demand for the INTERCEPT Blood System and Help Expand Access to Pathogen-Reduced Blood Components to
About this update from Cerus Corporation
[{"type":"text","content":"\n10-Year Collaboration Will Support Growing Global Demand for the INTERCEPT Blood System and Help Expand Access to Pathogen-Reduced Blood Components to Patients\n\n CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq: CERS) today announced that it has signed a ten-year agreement with Fresenius Kabi for the production of INTERCEPT Blood System sets. This new contract replaces the current one with Fresenius Kabi that was set to expire in July 2025.\n\n“Our long-standing partnership with Fresenius Kabi has enabled us to ramp the adoption of our pathogen inactivation technology broadly around the globe, as we work to fulfill our mission of making the INTERCEPT Blood System the standard of care in transfusion medicine,” said William ‘Obi’ Greenman, president and chief executive officer of Cerus. “After working together for more than 20 years, we are pleased to have extended our partnership commitment to meet the capacity requirements necessitated by the growth of our global business. This new cooperation secures numerous benefits for our companies, our customers and our shareholders, and it makes our supply chain more robust as we grow over the next decade.”\n\nFresenius Kabi will continue producing sets for Cerus at its facility in La Châtre, France, and will also expand manufacturing operations to two new facilities, both located in the Caribbean. The addition of these sites will increase production volume for INTERCEPT Blood System sets and provide for the redundancy required for continuity of supply to Cerus’ large blood center and national transfusion service customers. Finally, with the expanded manufacturing footprint and increased production volumes, Cerus and Fresenius Kabi are focused on realizing additional economies of scale for both organizations.\n\n“Cerus has been a valued partner, and we are excited to be announcing this next stage of our longstanding partnership with them today,” stated Dr. Christian Hauer, Member of the Management Board Fresenius Kabi and President Fresenius Kabi MedTech. “With the INTERCEPT Blood System, Cerus offers a best-in-class pathogen reduction technology that many blood centers, hospitals, and patients across the globe rely on. We look forward to continuing to help Cerus transform the transfusion medicine field and improve blood safety and availability around the world with our h...